Literature DB >> 3937596

Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia.

M P Caraceni, E Corghi, S Ortolani, S Casazza, A D'Alberton, T Motta.   

Abstract

We studied 15 hyperprolactinemic women to evaluate possible modifications of bone mineral content after pharmacological treatment. Patients received a dopamine agonist (bromocriptine) for six months after which there was a significant decrease of prolactin plasma levels (P less than 0.01) and a significant increase of bone mineral content (P less than 0.05).

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3937596     DOI： 10.1007/bf02554932

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


  13 in total

Review 1.  Prolactin.

Authors:  A G Frantz
Journal:  N Engl J Med       Date:  1978-01-26       Impact factor: 91.245

2.  Calcitonin inhibition of physiological and stimulated prolactin secretion in rats.

Authors:  V R Olgiati; F Guidobono; G Luisetto; C Netti; C Bianchi; A Pecile
Journal:  Life Sci       Date:  1981-08-10       Impact factor: 5.037

3.  Decreased bone density in hyperprolactinemic women.

Authors:  A Klibanski; R M Neer; I Z Beitins; E C Ridgway; N T Zervas; J W McArthur
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

4.  Clinical and endocrine features of hyperprolactinaemic amenorrhoea.

Authors:  H S Jacobs; S Franks; M A Murray; M G Hull; S J Steele; J D Nabarro
Journal:  Clin Endocrinol (Oxf)       Date:  1976-09       Impact factor: 3.478

5.  Effects of parathyroid hormone infusion and primary hyperparathyroidism on serum prolactin in man.

Authors:  J H Castro; J F Caro; H J Kim; J A Glennon
Journal:  J Clin Endocrinol Metab       Date:  1980-08       Impact factor: 5.958

6.  The interrelationships among prolactin, 1,25-dihydroxyvitamin D, and parathyroid hormone in humans.

Authors:  N D Adams; T L Garthwaite; R W Gray; T C Hagen; J Lemann
Journal:  J Clin Endocrinol Metab       Date:  1979-10       Impact factor: 5.958

7.  Effects of calcitonin on basal and thyrotropin-releasing hormone-stimulated prolactin secretion in man.

Authors:  R Isaac; R Merceron; G Caillens; J P Raymond; R Ardaillou
Journal:  J Clin Endocrinol Metab       Date:  1980-06       Impact factor: 5.958

8.  Role of pituitary hormones in regulating renal vitamin D metabolism in man.

Authors:  D J Brown; E Spanos; I MacIntyre
Journal:  Br Med J       Date:  1980-02-02

9.  Bone density in amenorrheic women with and without hyperprolactinemia.

Authors:  J A Schlechte; B Sherman; R Martin
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

10.  High sensitivity to calcitonin of prolactin-secreting control in lactating rats.

Authors:  V R Olgiati; C Netti; F Guidobono; A Pecile
Journal:  Endocrinology       Date:  1982-08       Impact factor: 4.736
View more
  4 in total

1.  Reversal of severe osteopenia in a patient with hyperprolactinemia treated with bromocriptine.

Authors:  J S Lindberg; F O Kolb; R A Blau; M R Powell
Journal:  West J Med       Date:  1988-09

Review 2.  The effects of hyperprolactinemia on bone and fat.

Authors:  Amal Shibli-Rahhal; Janet Schlechte
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

3.  Bone density in women with prolactinoma treated with dopamine agonists.

Authors:  Erika Cesar de Oliveira Naliato; Alice Helena Dutra Violante; Dayse Caldas; Maria Lucia Fleiuss Farias; Isabela Bussade; Adilson Lamounier Filho; Christiane Rezende Loureiro; Rosita Fontes; Yolanda Schrank; Thaissa Loures; Annamaria Colao
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

4.  Osteocalcin levels in patients with microprolactinoma before and during medical treatment.

Authors:  A Sartorio; A Conti; B Ambrosi; M Muratori; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.